Tuesday, June 7, 2022 – 2:01 pm
ABU DHABI, 7th June, 2020 (WAM) — Mubadala Investment Company (Mubadala) and EQTX Fund (EQT Private Equity) announced their acquisition of Invirotainer, the global provider of transportation chain solutions for temperature-sensitive and pharmaceuticals, owned by Senfin & Novo Holdings”, the company is valued at approximately 2.8 billion euros.
Millions of people around the world today depend on the safe delivery of medicines and biopharmaceuticals, which require temperature control to maintain their safety and quality.
Today, the difficulty of obtaining medicines is a cause of anxiety and confusion that affects disproportionately on less developed societies, in which the health situation is likely to be exacerbated by chronic diseases resulting from changing diets and lifestyles, as well as cases of air and water pollution.
Envirotainer expands access to medicines, pharmaceuticals and vaccines with safe, reliable and efficient cold chain solutions, which are one of the most climate-friendly sourcing services in the industry.
Both Mubadala and EQT Private Equity seek to support and enhance the growth of the “Envirotainer” company in the next phase, by accelerating the process of expanding the company’s business in the Asia-Pacific region, and continuing the stable growth in its other core markets, by taking advantage of EQT Private Equity’s community-wide approach and Mubadala’s global network will work together to expand the use of newly launched CryoSure vials and continue the successful launch of the third generation of Releye containers, while investing in new technology innovations, Enhancing the process of digital transformation and sustainability in the field of operational operations.
On this occasion, Camilla McCabile-Langel, Head of Life Sciences Unit at Mubadala, said: “Invirotainer plays a very important role in the healthcare ecosystem, by ensuring reliable and safe drug delivery from pharmaceutical companies to hospitals and clinics, and from there to patients.. It will enhance the global presence. Both Mubadala and EQT have the Invirotainer position and role as a global provider of temperature-controlled drug transport and pharmaceuticals, and the company, as the undisputed market leader, will continue to excel in the field of developments and innovations in this sector through its future research and development process. We have great confidence in the company’s growth path, and will work closely with the company’s management, and our partners in “EQT”, to ensure its long-term success.”
Ali Farhani, Partner in the EQT Private Equity Advisory Team, said: “The ability to effectively control the temperature for air transportation of temperature-sensitive pharmaceuticals provides attractive investment opportunities in the growing biopharmaceutical market. Today, the Invirotainer is an attractive investment opportunity. , a leading global company with significant advantages at scale, superior operations and industry leading performance..Moreover, the company primarily works to enable access to life-saving medicines and pharmaceuticals, and delivers sustainable solutions with lower CO2 emissions levels compared to other We believe that the company has great growth potential, and we, with our partners in Mubadala, look forward to partnering and collaborating with the current management team, to unleash the company’s potential and capabilities.”
Invirotainer was established in 1985 in Stockholm, Sweden, where the company is headquartered and its research, development and production facilities. The company designs, manufactures and rents active temperature-controlled containers, primarily used for air freight of vital pharmaceutical products. With a fleet of approximately 6,700 containers worldwide and approximately 375 employees in 20 countries around the world, the company is a world leader in effective temperature control for the air transportation of temperature-sensitive medicines. Today, the company has more than 600 customers in All over the world, including many global pharmaceutical and biotechnology companies.
WAM/ Ahmed Al Nuaimi/ Reda Abdel Nour